The article by Mendi et al 1 reports that preprocedural elevated serum uric acid (SUA) level was an independent risk factor for the development of contrast-induced nephropathy (CIN) after primary percutaneous coronary intervention (pPCI) in patients with ST-segment elevation myocardial infarction (STEMI).
Serum uric acid level has been associated with various cardiovascular (CV) pathologies. [2] [3] [4] [5] Kaya et al 2 showed that SUA was significantly associated with severity, extent, and morphology of coronary atherosclerotic plaques. The SYN-TAX score (SS) is an indicator of the complexity of coronary lesions and calculated by combination of various angiographic parameters to predict the prognosis of various patient populations. 6 Elbasan et al 7 showed that SS and SUA levels were significant predictors of CIN in patients with STEMI undergoing pPCI. Furthermore, the logistic clinical SS (log CSS) includes clinical parameters such as age, creatinine clearance, and left ventricular ejection fraction besides angiographic parameters used in calculating the routine SS. 8 In a recent study, Ozturk et al 9 demonstrated that the log CSS predicted the occurrence of CIN after pPCI and proposed that log CSS might improve the accuracy of risk stratification for the development of CIN in patients undergoing pPCI. Although Mendi et al 1 presented the number of diseased vessels, their data lack the extent and complexity of coronary atherosclerotic lesions. Because of the association between SUA and the extent/severity/complexity of coronary artery disease, the authors should comment on whether SUA level in the development of CIN was really a diagnostic marker or an innocent bystander. Furthermore, statins can affect SUA levels. [10] [11] [12] [13] Those studies suggest that atorvastatin or rosuvastatin may be recommended when statins are used in patients at high risk of CV disorders and hyperuricemia. In the study by Mendi et al, 1 the subtypes of statin therapy have not been included. Also, this study did not provide information about cause-effect relationship between SUA and CIN. Such a result can be achieved by lowering SUA levels with drugs such as allopurinol before pPCI to show any change in the rate of CIN. 14, 15 In conclusion, SUA level is a diagnostic and prognostic biomarker for various CV diseases. However, its role in the development of CIN among patients with STEMI undergoing pPCI should be interpreted after considering several confounding factors.
